BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 20, 2006
View Archived Issues
Genzyme's First-Quarter Sales Below Expectations
Genzyme Corp.'s stock dipped on word that first-quarter revenues came in lower than expected, though the $730.8 million number represents a 16 percent rise over the same quarter last year. (BioWorld Today)
Read More
CV Therapeutics Gets Line Of Credit For Up To $200M
Read More
Parasite Infections May Provide Dual Anti-Inflammatory Defense
Read More
Canada's Labopharm Files For $76M IPO On Nasdaq
Read More
Clinic Roundup
Read More
Other News To Note
Read More